Antifungal drug response in an in vitro model of dermatophyte nail infection.

Despite terbinafine being fungicidal against Trichophyton rubrum in standard NCCLS assays and rapidly accumulating in nails in vivo, onychomycosis patients require prolonged terbinafine treatment to be cured. To investigate this, we developed a more clinically relevant onychomycosis in vitro test model. Human nail powder inoculated with T. rubrum and incubated in liquid RPMI 1640 salt medium, which did not support growth alone, developed extensive and invasive mycelial growth. Antifungal drugs were added at different concentrations and cultures incubated for 1 to 4 weeks. Fungal survival was determined by spreading cultures on PDA plates without drug and measuring CFU after 1 to 4 weeks incubation. Drug activity was expressed as the nail minimum fungicidal concentration (Nail-MFC) required for 99.9% elimination of viable fungus. Terbinafine Nail-MFC was 4 microg/ml after 1 week exposure, decreasing to 1 microg/ml after 4 weeks exposure, much higher than MFCs < or = 0.03 microg/ml determined in standard NCCLS MIC assays. In contrast, other clinically used drugs were unable to kill T. rubrum after 4 weeks incubation in this model. Invasive mycelial growth on nail appears to protect T. rubrum from the cidal action of systemic drugs, thus providing a rationale for the long treatment periods in onychomycosis.

[1]  N. Ryder,et al.  Comparison of In Vitro Activities of 17 Antifungal Drugs against a Panel of 20 Dermatophytes by Using a Microdilution Assay , 2003, Journal of Clinical Microbiology.

[2]  M. Ghannoum,et al.  Clinical Trichophyton rubrum Strain Exhibiting Primary Resistance to Terbinafine , 2003, Antimicrobial Agents and Chemotherapy.

[3]  B. Sigurgeirsson,et al.  Prevalence of onychomycosis in Iceland: a population-based study. , 2002, Acta dermato-venereologica.

[4]  N. Ryder,et al.  In vitro susceptibility of Microsporum canis and other dermatophyte isolates from veterinary infections during therapy with terbinafine or griseofulvin. , 2002, Medical mycology.

[5]  S. Stubb,et al.  Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole , 2002, The British journal of dermatology.

[6]  S. Veraldi,et al.  Leishmaniasis of the lip. , 2002, Acta dermato-venereologica.

[7]  B. Cribier,et al.  Long‐term efficacy of antifungals in toenail onychomycosis: a critical review , 2001, The British journal of dermatology.

[8]  J. Guarro,et al.  In Vitro Activities of 10 Antifungal Drugs against 508 Dermatophyte Strains , 2001, Antimicrobial Agents and Chemotherapy.

[9]  Y. Niwano,et al.  Comparison of in vitro antifungal activities of topical antimycotics launched in 1990s in Japan. , 2001, International journal of antimicrobial agents.

[10]  R. Summerbell,et al.  Comparative efficacies of commonly used disinfectants and antifungal pharmaceutical spray preparations against dermatophytic fungi. , 2001, Medical mycology.

[11]  R. Summerbell,et al.  Epidemiology of Malassezia yeasts associated with pityriasis versicolor in Ontario, Canada. , 2001, Medical mycology.

[12]  M. Rinaldi,et al.  Comparison of In Vitro Activities of Voriconazole and Five Established Antifungal Agents against Different Species of Dermatophytes Using a Broth Macrodilution Method , 2001, Journal of Clinical Microbiology.

[13]  J. Arrese,et al.  A Plea to Bridge the Gap Between Antifungals and the Management of Onychomycosis , 2001, American journal of clinical dermatology.

[14]  T. Takasuka Amino acid- or protein-dependent growth of Trichophyton mentagrophytes and Trichophyton rubrum. , 2000, FEMS immunology and medical microbiology.

[15]  J. Guarro,et al.  In vitro Susceptibility to Itraconazole, Clotrimazole, Ketoconazole and Terbinafine of 100 Isolates of Trichophyton rubrum , 2000, Chemotherapy.

[16]  B. Elewski,et al.  A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. , 2000, Journal of the American Academy of Dermatology.

[17]  M. Ghannoum,et al.  An evaluation of the in vitro activity of terbinafine. , 2000, Medical mycology.

[18]  M. Kawai,et al.  Fluorometric Assessment of In Vitro Antidermatophytic Activities of Antimycotics Based on Their Keratin-Penetrating Power , 2000, Journal of Clinical Microbiology.

[19]  M. Ghannoum,et al.  Antifungal Susceptibility Testing of Dermatophytes: Establishing a Medium for Inducing Conidial Growth and Evaluation of Susceptibility of Clinical Isolates , 2000, Journal of Clinical Microbiology.

[20]  H. Degreef,et al.  Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents. , 1999, European journal of dermatology : EJD.

[21]  B. Sigurgeirsson,et al.  Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis , 1999 .

[22]  D. Strachan,et al.  Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study. , 1999, BMJ.

[23]  E. Evans,et al.  Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. , 1999, BMJ.

[24]  C. Seebacher Grenzen der Kurzzeitbehandlung von Onychomykosen , 1998, Der Hautarzt.

[25]  A. Offidani,et al.  In vitro activity of terbinafine against clinical isolates of dermatophytes. , 1998, Medical mycology.

[26]  E. Evans Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. , 1998, Journal of the American Academy of Dermatology.

[27]  K. Hazen Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison. , 1998, Journal of the American Academy of Dermatology.

[28]  H. Gugnani,et al.  Keratin degradation by Scytalidium species and Fusarium solani , 1998, Mycoses.

[29]  C. Seebacher [Limits of brief treatment of onychomycoses]. , 1998, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[30]  M. Richardson Effect of Lamisil and azole antifungals in experimental nail infection. , 1997, Dermatology.

[31]  T. Nishikawa,et al.  Neutral red assay in minimum fungicidal concentrations of antifungal agents. , 1996, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[32]  M. Richardson,et al.  Early events in the invasion of the human nail plate by Trichophyton mentagrophytes , 1995, The British journal of dermatology.

[33]  S. Stubb,et al.  The prevalence of onychomycosis in Finland , 1995, The British journal of dermatology.

[34]  M. Richardson,et al.  Inhibitory effect of terbinafine on the invasion of nails by Trichophyton mentagrophytes. , 1995, Journal of American Academy of Dermatology.

[35]  R. Summerbell,et al.  The dermatophytes , 1995, Clinical microbiology reviews.

[36]  Y. Clayton Relevance of broad‐spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses , 1994, The British journal of dermatology.

[37]  L. Millérioux,et al.  Levels of terbinafine in plasma, stratum corneum, dermis–epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days , 1994, Clinical and experimental dermatology.

[38]  L. Millérioux,et al.  Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. , 1993, Acta dermato-venereologica.

[39]  N. Ryder,et al.  Terbinafine: Mode of action and properties of the squalene epoxidase inhibition , 1992, The British journal of dermatology.

[40]  G. Petrányi,et al.  Antifungal activity of the allylamine derivative terbinafine in vitro , 1987, Antimicrobial Agents and Chemotherapy.

[41]  Lin Jincai,et al.  The Principle of Integrating Theory with Practice Must Be Conscientiously Implemented in the Teaching of Humanities , 1986 .

[42]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.